Summary
This white paper discusses the evolving role of medical affairs within the pharmaceutical industry, particularly focusing on its transition into a strategic partner and healthcare integrator. It outlines three distinct eras of medical affairs: the first era centered on scientific expertise, the second era as a strategic partner, and the emerging third era characterized by the need for medical impact at scale. The paper identifies key challenges faced by medical affairs organizations, such as the slow adoption of scientific innovations in clinical settings and the need for enhanced partnerships with external stakeholders. It emphasizes the importance of transforming organizational culture and talent to meet the demands of this new era. The authors propose that medical affairs must not only adapt its operational strategies but also develop competencies in digital fluency, partnership building, and organizational navigation to effectively drive patient outcomes. The ZS Organization rEvolution framework is introduced as a guide for healthcare leaders to navigate these changes.
